All Stories

  1. Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies

    Article • Lung Cancer Targets and Therapy, November 2019, Taylor & Francis

    FILIPPO DE MARINIS

  2. Diagnosis and first-line treatment of non-small cell lung cancer in the era of novel immunotherapy: recommendations for clinical practice

    Article • Expert Review of Respiratory Medicine, January 2019, Taylor & Francis

    FILIPPO DE MARINIS, MARIA RITA MIGLIORINO

  3. Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy

    Article • Current Clinical Pharmacology, October 2018, Bentham Science Publishers

    Ester Simeone, FILIPPO DE MARINIS

  4. Stereotactic body radiation therapy for mediastinal lymph node metastases: how do we fly in a ‘no-fly zone’?

    Article • Acta Oncologica, October 2018, Taylor & Francis

    FILIPPO DE MARINIS

  5. Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-s...

    Article • Current Medical Research and Opinion, March 2018, Taylor & Francis

    FILIPPO DE MARINIS

  6. Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice

    Article • OncoTargets and Therapy, October 2016, Dove Medical Press

    FILIPPO DE MARINIS

  7. Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)

    Article • OncoTargets and Therapy, August 2015, Dove Medical Press

    FILIPPO DE MARINIS

  8. Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E

    Article • OncoTargets and Therapy, May 2014, Taylor & Francis

    FILIPPO DE MARINIS